Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

THOUSAND OAKS, Calif., June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Goldman Sachs 46 th Annual Global Healthcare Conference at 9:20 ...

Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing ...

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.

The Federal Court has granted Alexion a declaration of infringement and an injunction preventing Amgen from manufacturing, ...

Alan Berro of American Funds Washington Mutual focuses on buying good companies at a decent price, such as Amgen, Comcast, ...